Children

Etravirine is safe and effective in treatment-experienced children and adolescents. When combined with an optimised background regimen and dosed either by weight (5.2mg/kg) or 200mg twice a day etravirine suppressed viral load below 50 copies/ml in 56% of 101 children and adolescents.1

References

  1. Tudor-Williams G et al. Etravirine in treatment-experienced, HIV-1 infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Med 15(9): 513-24, 2014
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.